CoChat
Sign Up
Cited by 132Pancreatic function and diabetesDiabetes Treatment and ManagementDiabetes and associated disorders

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells

Open access
El, K., Gray, S. M., Capozzi, M. E., Knuth, E. R., Jin, E., Svendsen, B., Clifford, A., Brown, J. L. +7 more·2021·Science Advances
DOI 10.1126/sciadv.abf1948PMC PMC7954443
Open this paper in CoChat — free account

Abstract

GIPR activity in α cells is required for the complete metabolic response to a meal.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.abf1948

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 38 · Cited by 132

Research works printed but not linked: 28

  1. [3]D. J. Drucker, Advances in oral peptide therapeutics. Nat. Rev. Drug Discov. 19, 277– 289 (2020). 31848464
  2. [5]T. Vilsboll, T. Krarup, J. Sonne, S. Madsbad, A. Vølund, A. G. Juul, J. J. Holst, Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 88, 2706– 2713 (2003). 12788877
  3. [8]K. El, J. E. Campbell, The role of GIP in α-cells and glucagon secretion. Peptides 125, 170213 (2020). 31785304 PMC7580028
  4. [9]C. W. Chia, O. D. Carlson, W. Kim, Y. K. Shin, C. P. Charles, H. S. Kim, D. L. Melvin, J. M. Egan, Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58, 1342– 1349 (2009). 19276444 PMC2682676
  5. [11]E. C. Opara, V. L. Go, Influence of gastric inhibitory polypeptide (GIP) and glucose on the regulation of glucagon secretion by pancreatic alpha cells. Regul. Pept. 32, 65– 73 (1991). 2034823
  6. [12]A. H. Sparre-Ulrich, M. N. Gabe, L. S. Gasbjerg, C. B. Christiansen, B. Svendsen, B. Hartmann, J. J. Holst, M. M. Rosenkilde, GIP(3–30)NH 2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release. Biochem. Pharmacol. 131, 78– 88 (2017). 28237651
  7. [14]C. W. Chia, J. O. Odetunde, W. Kim, O. D. Carlson, L. Ferrucci, J. M. Egan, GIP contributes to islet trihormonal abnormalities in type 2 diabetes. J. Clin. Endocrinol. Metab. 99, 2477– 2485 (2014). 24712564 PMC4079310
  8. [15]A. Lund, T. Vilsboll, J. I. Bagger, J. J. Holst, F. K. Knop, The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 300, E1038– E1046 (2011). 21386059
  9. [16]M. E. Capozzi, B. Svendsen, S. E. Encisco, S. L. Lewandowski, M. D. Martin, H. Lin, J. L. Jaffe, R. W. Coch, J. M. Haldeman, P. E. MacDonald, M. J. Merrins, D. A. D’Alessio, J. E. Campbell, β cell tone is defined by proglucagon peptides through cAMP signaling. JCI Insight 4, e126742 (2019). PMC6483521 30720465
  10. [17]M. E. Capozzi, J. B. Wait, J. Koech, A. N. Gordon, R. W. Coch, B. Svendsen, B. Finan, D. A. D’Alessio, J. E. Campbell, Glucagon lowers glycemia when beta-cells are active. JCI Insight 5, e129954 (2019). PMC6777806 31335319
  11. [18]B. Svendsen, O. Larsen, M. B. N. Gabe, C. B. Christiansen, M. M. Rosenkilde, D. J. Drucker, J. J. Holst, Insulin secretion depends on intra-islet glucagon signaling. Cell Rep. 25, 1127– 1134.e2 (2018). 30380405
  12. [19]L. Zhu, D. Dattaroy, J. Pham, L. Wang, L. F. Barella, Y. Cui, K. J. Wilkins, B. L. Roth, U. Hochgeschwender, F. M. Matschinsky, K. H. Kaestner, N. M. Doliba, J. Wess, Intra-islet glucagon signaling is critical for maintaining glucose homeostasis. JCI Insight 5, e127994 (2019). PMC6542600 31012868
  13. [21]J. J. Meier, B. Gallwitz, N. Siepmann, J. J. Holst, C. F. Deacon, W. E. Schmidt, M. A. Nauck, Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46, 798– 801 (2003). 12764578
  14. [22]A. M. Ackermann, J. Zhang, A. Heller, A. Briker, K. H. Kaestner, High-fidelity glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting. Mol. Metab. 6, 236– 244 (2017). 28271030 PMC5323890
  15. [23]J. E. Campbell, J. R. Ussher, E. E. Mulvihill, J. Kolic, L. L. Baggio, X. Cao, Y. Liu, B. J. Lamont, T. Morii, C. J. Streutker, N. Tamarina, L. H. Philipson, J. L. Wrana, P. E. MacDonald, D. J. Drucker, TCF1 links GIPR signaling to the control of beta cell function and survival. Nat. Med. 22, 84– 90 (2016). 26642437
  16. [24]S. M. Gray, Y. Xin, E. C. Ross, B. M. Chazotte, M. E. Capozzi, K. el, B. Svendsen, P. Ravn, K. W. Sloop, J. Tong, J. Gromada, J. E. Campbell, D. A. D’Alessio, Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells. J. Biol. Chem. 295, 11529– 11541 (2020). 32554468 PMC7450118
  17. [25]R. Rodriguez-Diaz, R. D. Molano, J. R. Weitz, M. H. Abdulreda, D. M. Berman, B. Leibiger, I. B. Leibiger, N. S. Kenyon, C. Ricordi, A. Pileggi, A. Caicedo, P.-O. Berggren, Paracrine interactions within the pancreatic islet determine the glycemic set point. Cell Metab. 27, 549– 558.e4 (2018). 29514065 PMC5872154
  18. [26]A. P. Chambers, J. E. Sorrell, A. Haller, K. Roelofs, C. R. Hutch, K.-S. Kim, R. Gutierrez-Aguilar, B. Li, D. J. Drucker, D. A. D’Alessio, R. J. Seeley, D. A. Sandoval, The role of pancreatic preproglucagon in glucose homeostasis in mice. Cell Metab. 25, 927– 934.e3 (2017). 28325479 PMC5385998
  19. [27]M. A. Nauck, E. Bartels, C. Orskov, R. Ebert, W. Creutzfeldt, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76, 912– 917 (1993). 8473405
  20. [28]E. Samols, G. Marri, V. Marks, Promotion of insulin secretion by glucagon. Lancet 2, 415– 416 (1965). 14346763
  21. [29]E. P. Smith, Z. An, C. Wagner, A. G. Lewis, E. B. Cohen, B. Li, P. Mahbod, D. Sandoval, D. Perez-Tilve, N. Tamarina, L. H. Philipson, D. A. Stoffers, R. J. Seeley, D. A. D’Alessio, The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 19, 1050– 1057 (2014). 24836562 PMC4109713
  22. [31]K. El, M. E. Capozzi, J. E. Campbell, Repositioning the alpha cell in postprandial metabolism. Endocrinology 161, bqaa169 (2020). 32964214 PMC7899437
  23. [33]K. D. Galsgaard, S. L. Jepsen, S. A. S. Kjeldsen, J. Pedersen, N. J. Wewer Albrechtsen, J. J. Holst, Alanine, arginine, cysteine, and proline, but not glutamine, are substrates for, and acute mediators of, the liver-α-cell axis in female mice. Am. J. Physiol. Endocrinol. Metab. 318, E920– E929 (2020). 32255678
  24. [34]A. Vikram, G. Jena, S961, an insulin receptor antagonist causes hyperinsulinemia, insulin-resistance and depletion of energy stores in rats. Biochem. Biophys. Res. Commun. 398, 260– 265 (2010). 20599729
  25. [35]E. D. Dean, M. Li, N. Prasad, S. N. Wisniewski, A. V. Deylen, J. Spaeth, L. Maddison, A. Botros, L. R. Sedgeman, N. Bozadjieva, O. Ilkayeva, A. Coldren, G. Poffenberger, A. Shostak, M. C. Semich, K. I. Aamodt, N. Phillips, H. Yan, E. Bernal-Mizrachi, J. D. Corbin, K. C. Vickers, S. E. Levy, C. Dai, C. Newgard, W. Gu, R. Stein, W. Chen, A. C. Powers, Interrupted glucagon signaling reveals hepatic α cell axis and role for L-glutamine in α cell proliferation. Cell Metab. 25, 1362– 1373.e5 (2017). 28591638 PMC5572896
  26. [36]C. Longuet, A. M. Robledo, E. D. Dean, C. Dai, S. Ali, I. McGuinness, V. de Chavez, P. M. Vuguin, M. J. Charron, A. C. Powers, D. J. Drucker, Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: Evidence for a circulating α-cell growth factor. Diabetes 62, 1196– 1205 (2013). 23160527 PMC3609565
  27. [37]B. S. Muntean, S. Zucca, C. M. MacMullen, M. T. Dao, C. Johnston, H. Iwamoto, R. D. Blakely, R. L. Davis, K. A. Martemyanov, Interrogating the spatiotemporal landscape of neuromodulatory GPCR signaling by real-time imaging of cAMP in intact neurons and circuits. Cell Rep. 22, 255– 268 (2018). 29298426 PMC5761078
  28. [38]L. Madisen, A. R. Garner, D. Shimaoka, A. S. Chuong, N. C. Klapoetke, L. Li, A. van der Bourg, Y. Niino, L. Egolf, C. Monetti, H. Gu, M. Mills, A. Cheng, B. Tasic, T. N. Nguyen, S. M. Sunkin, A. Benucci, A. Nagy, A. Miyawaki, F. Helmchen, R. M. Empson, T. Knöpfel, E. S. Boyden, R. C. Reid, M. Carandini, H. Zeng, Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. Neuron 85, 942– 958 (2015). 25741722 PMC4365051

Authors
El, K., Gray, S. M., Capozzi, M. E., Knuth, E. R., Jin, E., Svendsen, B., Clifford, A., Brown, J. L., Encisco, S. E., Chazotte, B. M., Sloop, K. W., Nunez, D. J., Merrins, M. J., D’Alessio, D. A., & Campbell, J. E.
Affiliations
  • Duke University (US)
  • University of Wisconsin–Madison (US)
  • Eli Lilly (United States) (US)
Corresponding author
Campbell, J. E.
ORCID
Venue
Science Advances
Publisher
American Association for the Advancement of Science (AAAS)
Published
2021-03-12
Volume
7
Issue
11
ISSN
2375-2548 (ISSN-L)
DOI
10.1126/sciadv.abf1948
PMC
PMC7954443
OpenAlex
W3134075201
Cited by
132
References
38
Citations by year
2026: 18 · 2025: 23 · 2024: 31 · 2023: 26 · 2022: 25 · 2021: 9
FWCI
21.38
Type
journal article
Language
en
Open access
Licence
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (DK007012, DK116542, DK123075, DK125353, DK101991)
  • American Diabetes Association (1-18-JDF-017)
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
glucose-dependent insulinotropic polypeptide, GIP receptor, alpha cells, pancreatic beta cells, glucagon secretion, insulin secretion, incretin effect, glucose tolerance, amino acid stimulation
MeSH terms
Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon, Glucose, Humans, Receptors, Gastrointestinal Hormone, Receptors, G-Protein-Coupled, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review